Tag: treatment

Optimized capital structure, retiring short-term maturing debt

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

GEORGE TOWN, Cayman Islands, June 24, 2026 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, today announced that its Cayman Islands retail water utility, Cayman Water Company Limited, has received a new license from the Utility Regulation and Competition Office of the Cayman Islands (“OfReg”) to provide potable water service to customers in its licensed service areas on Grand Cayman.

NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Prospect Floating Rate and Alternative Income Fund, Inc. (“Prospect Floating Rate and Alternative Income Fund” or the “Fund”), announced today that the Fund’s Board of Directors has declared the monthly “base” cash common shareholder distribution and its quarterly cash “bonus” common shareholder distribution for June 2026.

NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- The American Kennel Club (AKC^®), a not-for-profit organization that is the world’s largest registry of purebred and mixed-breed dogs, and a leading voice for canine welfare and responsible ownership, applauds the U.S. Senate Agriculture Committee’s base text for the 2026 Senate Agricultural Authorization Act, the “Farm Bill 2.0”. This measure accompanies and shares important positive priorities with the recently passed House Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026.) The bill reauthorizes key U.S. Department of Agriculture (USDA) programs through 2031 and serves as an important vehicle to address federal priorities in the federal Animal Welfare Act (AWA).

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).

Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients